Gut microbiota in kidney disease and hypertension

Pharmacological Research

Volumn 130, Issue , 2018, Pages 198-203

  Antza, C ^a   Stabouli, S ^a   Kotsis, V ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Gut dysbiosis; Gut microbiota; Hypertension; Kidney disease; Microbiome

Indexed keywords

CYTOKINE; PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID; TRIMETHYLAMINE OXIDE;

BLOOD PRESSURE; BLOOD VESSEL PARAMETERS; BODY WEIGHT LOSS; DIET THERAPY; DISEASE ASSOCIATION; EXERCISE; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INTESTINE FLORA; KIDNEY DISEASE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAGING; ANIMAL; CHRONIC KIDNEY FAILURE; DYSBIOSIS; MICROBIOLOGY;

ANIMALS; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC;

EID: 85042908604     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2018.02.028     Document Type: Review

References (73)

1. Noverr, M.C., Huffnagle, G.B., Does the microbiota regulate immune responses outside the gut?. Trends Microbiol. 12:12 (2004), 562–568.
2. Mariat, D., Firmesse, O., Levenez, F., Guimaraes, V., Sokol, H., Dore, J., et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol., 9, 2009, 123.
3. Jandhyala, S.M., Talukdar, R., Subramanyam, C., Vuyyuru, H., Sasikala, M., Nageshwar Reddy, D., Role of the normal gut microbiota. World J. Gastroenterol. 21:29 (2015), 8787–8803.
4. Sekirov, I., Russell, S.L., Antunes, L.C., Finlay, B.B., Gut microbiota in health and disease. Physiol. Rev. 90:3 (2010), 859–904.
5. Yan, Q., Gu, Y., Li, X., Yang, W., Jia, L., Chen, C., et al. Alterations of the gut microbiome in hypertension. Front. Cell. Infect. Microbiol., 7, 2017, 381.
6. Marques, F.Z., Mackay, C.R., Kaye, D.M., Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat. Rev. Cardiol. 15:1 (2018), 20–32.
7. Al Khodor, S., Reichert, B., Shatat, I.F., The microbiome and blood pressure: can microbes regulate our blood pressure?. Front. Pediatr., 5, 2017, 138.
8. Afsar, B., Vaziri, N.D., Aslan, G., Tarim, K., Kanbay, M., Gut hormones and gut microbiota: implications for kidney function and hypertension. J. Am. Soc. Hypertens. 10:12 (2016), 954–961.
9. Mishima, R.S., Elliott, A.D., Sanders, P., Linz, D., Gastrointestinal sodium absorption, microbiome, and hypertension. Nat. Rev. Cardiol., 14(11), 2017, 693.
10. Mittal, R., Debs, L.H., Patel, A.P., Nguyen, D., Patel, K., O'Connor, G., et al. Neurotransmitters: the critical modulators regulating gut-brain axis. J. Cell. Physiol. 232:9 (2017), 2359–2372.
11. Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19:5 (2013), 576–585.
12. Flint, H.J., Bayer, E.A., Rincon, M.T., Lamed, R., White, B.A., Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat. Rev. Microbiol. 6:2 (2008), 121–131.
13. Vanholder, R., Schepers, E., Pletinck, A., Nagler, E.V., Glorieux, G., The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J. Am. Soc. Nephrol. 25:9 (2014), 1897–1907.
14. Yamazaki, K., Katoh, H., Yamamoto, N., Kurihara, K., Iobe, H., Sonoda, J., et al. Characterization of new inbred strains of Dahl-Iwai salt-sensitive and salt-resistant rats. Lab. Anim. Sci. 44:5 (1994), 462–467.
15. Mell, B., Jala, V.R., Mathew, A.V., Byun, J., Waghulde, H., Zhang, Y., et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol. Genomics 47:6 (2015), 187–197.
16. Yang, T., Santisteban, M.M., Rodriguez, V., Li, E., Ahmari, N., Carvajal, J.M., et al. Gut dysbiosis is linked to hypertension. Hypertension 65:6 (2015), 1331–1340.
17. Marques, F.Z., Nelson, E., Chu, P.Y., Horlock, D., Fiedler, A., Ziemann, M., et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 135:10 (2017), 964–977.
18. Karbach, S.H., Schonfelder, T., Brandao, I., Wilms, E., Hormann, N., Jackel, S., et al. Gut microbiota promote angiotensin II-induced arterial hypertension and vascular dysfunction. J. Am. Heart Assoc., 5, 2016, 9.
19. Yoshifuji, A., Wakino, S., Irie, J., Tajima, T., Hasegawa, K., Kanda, T., et al. Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol. Dial. Transplant. 31:3 (2016), 401–412.
20. Kieffer, D.A., Piccolo, B.D., Vaziri, N.D., Liu, S., Lau, W.L., Khazaeli, M., et al. Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am. J. Physiol. Renal Physiol. 310:9 (2016), F857–71.
21. Kotsis, V., Nilsson, P., Grassi, G., Mancia, G., Redon, J., Luft, F., et al. New developments in the pathogenesis of obesity-induced hypertension. J. Hypertens. 33:8 (2015), 1499–1508.
22. Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., et al. Chronic kidney disease: global dimension and perspectives. Lancet 382:9888 (2013), 260–272.
23. Sabatino, A., Regolisti, G., Cosola, C., Gesualdo, L., Fiaccadori, E., Intestinal microbiota in type 2 diabetes and chronic kidney disease. Curr. Diab. Rep., 17(3), 2017, 16.
24. Romano, K.A., Vivas, E.I., Amador-Noguez, D., Rey, F.E., Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. MBio, 6(2), 2015, e02481.
25. Craciun, S., Balskus, E.P., Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl. Acad. Sci. U. S. A. 109:52 (2012), 21307–21312.
26. Zhu, Y., Jameson, E., Crosatti, M., Schafer, H., Rajakumar, K., Bugg, T.D., et al. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc. Natl. Acad. Sci. U. S. A. 111:11 (2014), 4268–4273.
27. Gregory, J.C., Buffa, J.A., Org, E., Wang, Z., Levison, B.S., Zhu, W., et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J. Biol. Chem. 290:9 (2015), 5647–5660.
28. Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:7341 (2011), 57–63.
29. Tuso, P., Stoll, S.R., Li, W.W., A plant-based diet, atherogenesis, and coronary artery disease prevention. Perm J. 19:1 (2015), 62–67.
30. Ufnal, M., Jazwiec, R., Dadlez, M., Drapala, A., Sikora, M., Skrzypecki, J., Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can. J. Cardiol. 30:12 (2014), 1700–1705.
31. Mueller, D.M., Allenspach, M., Othman, A., Saely, C.H., Muendlein, A., Vonbank, A., et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis 243:2 (2015), 638–644.
32. Tang, W.H., Wang, Z., Kennedy, D.J., Wu, Y., Buffa, J.A., Agatisa-Boyle, B., et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 116:3 (2015), 448–455.
33. Hai, X., Landeras, V., Dobre, M.A., DeOreo, P., Meyer, T.W., Hostetter, T.H., Mechanism of prominent trimethylamine oxide (TMAO) accumulation in hemodialysis patients. PLoS One, 10(12), 2015, e0143731.
34. Shafi, T., Powe, N.R., Meyer, T.W., Hwang, S., Hai, X., Melamed, M.L., et al. Trimethylamine N-oxide and cardiovascular events in hemodialysis patients. J. Am. Soc. Nephrol. 28:1 (2017), 321–331.
35. Mafune, A., Iwamoto, T., Tsutsumi, Y., Nakashima, A., Yamamoto, I., Yokoyama, K., et al. Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study. Clin. Exp. Nephrol. 20:5 (2016), 731–739.
36. Asarat, M., Apostolopoulos, V., Vasiljevic, T., Donkor, O., Short-chain fatty acids regulate cytokines and Th17/Treg cells in human peripheral blood mononuclear cells in vitro. Immunol. Invest. 45:3 (2016), 205–222.
37. Campbell, J.M., Fahey, G.C. Jr., Wolf, B.W., Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J. Nutr. 127:1 (1997), 130–136.
38. Smiricky-Tjardes, M.R., Grieshop, C.M., Flickinger, E.A., Bauer, L.L., Fahey, G.C. Jr., Dietary galactooligosaccharides affect ileal and total-tract nutrient digestibility, ileal and fecal bacterial concentrations, and ileal fermentative characteristics of growing pigs. J. Anim. Sci. 81:10 (2003), 2535–2545.
39. Andrade-Oliveira, V., Amano, M.T., Correa-Costa, M., Castoldi, A., Felizardo, R.J., de Almeida, D.C., et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J. Am. Soc. Nephrol. 26:8 (2015), 1877–1888.
40. Pluznick, J.L., Zou, D.J., Zhang, X., Yan, Q., Rodriguez-Gil, D.J., Eisner, C., et al. Functional expression of the olfactory signaling system in the kidney. Proc. Natl. Acad. Sci. U. S. A. 106:6 (2009), 2059–2064.
41. Pluznick, J.L., Protzko, R.J., Gevorgyan, H., Peterlin, Z., Sipos, A., Han, J., et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc. Natl. Acad. Sci. U. S. A. 110:11 (2013), 4410–4415.
42. Anders, H.J., Andersen, K., Stecher, B., The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 83:6 (2013), 1010–1016.
43. Ramezani, A., Raj, D.S., The gut microbiome, kidney disease, and targeted interventions. J. Am. Soc. Nephrol. 25:4 (2014), 657–670.
44. Ardalan, M., Vahed, S.Z., Gut microbiota and renal transplant outcome. Biomed. Pharmacother. 90 (2017), 229–236.
45. Biancardi, V.C., Bomfim, G.F., Reis, W.L., Al-Gassimi, S., Nunes, K.P., The interplay between angiotensin II, TLR4 and hypertension. Pharmacol. Res. 120 (2017), 88–96.
46. Rudemiller, N.P., Crowley, S.D., The role of chemokines in hypertension and consequent target organ damage. Pharmacol. Res. 119 (2017), 404–411.
47. McIntyre, C.W., Harrison, L.E., Eldehni, M.T., Jefferies, H.J., Szeto, C.C., John, S.G., et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6:1 (2011), 133–141.
48. Kim, S., Rodriguez, V., Santisteban, M., Yang, T., Qi, Y., Raizada, M., et al. 6b. 07: Hypertensive patients exhibit gut microbial dysbiosis and an increase in TH17 cells. J. Hypertens. 33:Suppl. 1 (2015), e77–e78.
49. Iraporda, C., Errea, A., Romanin, D.E., Cayet, D., Pereyra, E., Pignataro, O., et al. Lactate and short chain fatty acids produced by microbial fermentation downregulate proinflammatory responses in intestinal epithelial cells and myeloid cells. Immunobiology 220:10 (2015), 1161–1169.
50. Kang, Y., Cai, Y., Gut microbiota and hypertension: from pathogenesis to new therapeutic strategies. Clin. Res. Hepatol. Gastroenterol., 2017, 10.1016/j.clinre.2017.09.006 Nov 1, pii: S2210-7401(17)30215-2 [Epub ahead of print].
51. Kim, M., Shin, H.K., The water-soluble extract of chicory influences serum and liver lipid concentrations, cecal short-chain fatty acid concentrations and fecal lipid excretion in rats. J. Nutr. 128:10 (1998), 1731–1736.
52. Burke, V., Hodgson, J.M., Beilin, L.J., Giangiulioi, N., Rogers, P., Puddey, I.B., Dietary protein and soluble fiber reduce ambulatory blood pressure in treated hypertensives. Hypertension 38:4 (2001), 821–826.
53. Eliasson, K., Ryttig, K.R., Hylander, B., Rossner, S., A dietary fibre supplement in the treatment of mild hypertension. A randomized, double-blind, placebo-controlled trial. J. Hypertens. 10:2 (1992), 195–199.
54. Lee, Y.P., Mori, T.A., Puddey, I.B., Sipsas, S., Ackland, T.R., Beilin, L.J., et al. Effects of lupin kernel flour-enriched bread on blood pressure: a controlled intervention study. Am. J. Clin. Nutr. 89:3 (2009), 766–772.
55. He, J., Streiffer, R.H., Muntner, P., Krousel-Wood, M.A., Whelton, P.K., Effect of dietary fiber intake on blood pressure: a randomized, double-blind, placebo-controlled trial. J. Hypertens. 22:1 (2004), 73–80.
56. Pavan, M., Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease. Minerva Urol. Nefrol. 68:2 (2016), 222–226.
57. Saad, M.F., Rewers, M., Selby, J., Howard, G., Jinagouda, S., Fahmi, S., et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension 43:6 (2004), 1324–1331.
58. Streppel, M.T., Arends, L.R., van‘t Veer, P., Grobbee, D.E., Geleijnse, J.M., Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch. Intern. Med. 165:2 (2005), 150–156.
59. Poesen, R., Evenepoel, P., de Loor, H., Delcour, J.A., Courtin, C.M., Kuypers, D., et al. The influence of prebiotic arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease: a randomized controlled trial. PLoS One, 11(4), 2016, e0153893.
60. Sanders, M.E., Probiotics: definition, sources, selection, and uses. Clin. Infect. Dis. 46:Suppl. 2 (2008), S58–S61 (discussion S144-51).
61. Agerholm-Larsen, L., Raben, A., Haulrik, N., Hansen, A.S., Manders, M., Astrup, A., Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur. J. Clin. Nutr. 54:4 (2000), 288–297.
62. Naruszewicz, M., Johansson, M.L., Zapolska-Downar, D., Bukowska, H., Effect of Lactobacillus plantarum 299 v on cardiovascular disease risk factors in smokers. Am. J. Clin. Nutr. 76:6 (2002), 1249–1255.
63. Lin, P.P., Hsieh, Y.M., Kuo, W.W., Lin, Y.M., Yeh, Y.L., Lin, C.C., et al. Probiotic-fermented purple sweet potato yogurt activates compensatory IGFIR/PI3K/Akt survival pathways and attenuates cardiac apoptosis in the hearts of spontaneously hypertensive rats. Int. J. Mol. Med. 32:6 (2013), 1319–1328.
64. Kawase, M., Hashimoto, H., Hosoda, M., Morita, H., Hosono, A., Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. J. Dairy Sci. 83:2 (2000), 255–263.
65. Dong, J.Y., Szeto, I.M., Makinen, K., Gao, Q., Wang, J., Qin, L.Q., et al. Effect of probiotic fermented milk on blood pressure: a meta-analysis of randomised controlled trials. Br. J. Nutr. 110:7 (2013), 1188–1194.
66. Ranganathan, N., Ranganathan, P., Friedman, E.A., Joseph, A., Delano, B., Goldfarb, D.S., et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv. Ther. 27:9 (2010), 634–647.
67. Ranganathan, N., Friedman, E.A., Tam, P., Rao, V., Ranganathan, P., Dheer, R., Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr. Med. Res. Opin. 25:8 (2009), 1919–1930.
68. Miranda Alatriste, P.V., Urbina Arronte, R., Gomez Espinosa, C.O., Espinosa Cuevas Mde, L., Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr. Hosp. 29:3 (2014), 582–590.
69. Natarajan, R., Pechenyak, B., Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Res. Int., 2014, 2014, 568571, 10.1155/2014/568571 Epub 2014 Jul 24.
70. Wang, I.K., Wu, Y.Y., Yang, Y.F., Ting, I.W., Lin, C.C., Yen, T.H., et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef. Microbes 6:4 (2015), 423–430.
71. Pandey, K.R., Naik, S.R., Vakil, B.V., Probiotics, prebiotics and synbiotics- a review. J. Food Sci. Technol. 52:12 (2015), 7577–7587.
72. Xu, J., Ahren, I.L., Prykhodko, O., Olsson, C., Ahrne, S., Molin, G., Intake of blueberry fermented by lactobacillus plantarum affects the gut microbiota of L-NAME treated rats. Evid. Based Compl. Altern. Med., 2013, 2013, 809128.
73. Rossi, M., Johnson, D.W., Morrison, M., Pascoe, E.M., Coombes, J.S., Forbes, J.M., et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin. J. Am. Soc. Nephrol. 11:2 (2016), 223–231.